Erika Rodríguez-Lobato, Departamento de Cirugía Dermatológica y Dermato-Oncología, Hospital General Dr. Manuel Gea González, Ciudad de México, México
Luis E. Cano-Aguilar, Servicio de Dermatología, Hospital General Dr. Manuel Gea González, Ciudad de México, México
Arely Tamariz-Campillo, Departamento de Dermatología. Hospital General Dr. Manuel Gea González, Ciudad de México, México
Guillermo Ramos-Rodríguez, Departamento de Dermatología. Hospital General Dr. Manuel Gea González, Ciudad de México, México
Verónica Fonte-Ávalos, Departamento de Cirugía Dermatológica y Dermato-Oncología, Hospital General Dr. Manuel Gea González, Ciudad de México, México
Mariana De Anda-Juárez, Departamento de Cirugía Dermatológica y Dermato-Oncología, Hospital General Dr. Manuel Gea González, Ciudad de México, México
Introduction: Myxoid neurothekeoma is a rare benign cutaneous neoplasm located in the reticular dermis or subcutaneous cellular tissue. It is most frequently located in the head in 33% of reported cases, with a higher incidence in young women. Surgical resection is the treatment of choice. Objective: To describe the clinical and histopathological characteristics of patients with myxoid neurothekeoma in a dermatology center. Method: An observational, descriptive, retrospective study was performed in patients with myxoid neurothekeoma. Results: Three cases reported as myxoid neurothekeoma were found, from 1992 to 2022. Conclusions: Myxoid neurothekeoma is a rare and nonspecific dermatosis, whose diagnosis is based on histopathological and immunohistochemical confirmation. Age and topography are two clinical tools that suggest the diagnosis. The most important immunomarkers are S100, CD10,CD63 (NKI/C3) and GFAP. The therapeutic standard is surgical excision.
Keywords: Myxoma. Neurothekeoma myxoid. Neurothekeoma hypocellular. Myofibroblastic tumor. Nerve sheath tumor.